FDA Determines Regulatory Review Period for BYFAVO Patent Extension

Summary

The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of BYFAVO, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).